microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer

Background:The purpose of this study was to identify prostate cancer (PC) oncogenic microRNAs (miRs) based on miR microarray and to investigate whether these oncogenic miRs may be useful as PC biomarkers.Methods:Initially, we carried out miR microarray and real-time PCR using RWPE-1, PC-3, DU-145 and LNCaP cells. To investigate the function of miR-183, we used a miR-183 knockdown inhibitor in cell growth and wound-healing assays. We used several algorithms and confirmed that they are directly regulated by miR-183.Results:We identified three potential oncogenic miRs (miR-146a, miR-183 and miR-767-5P). The expression of miR-183 in PC cells (PC-3, DU-145 and LNCaP) was upregulated compared with RWPE-1 cells. MiR-183 expression was also significantly higher in PC tissues compared with that in matched normal prostate tissues. Additionally, miR-183 expression was correlated with higher prostate-specific antigen, higher pT and shorter overall survival. MiR-183 knockdown decreased cell growth and motility in PC cells and significantly decreased prostate tumour growth in in vivo nude mice experiments. We identified Dkk-3 and SMAD4 as potential target genes of miR-183.Conclusion:Our data suggest that oncogenic miR-183 may be useful as a new PC biomarker and that inhibition of miR-183 expression may be therapeutically beneficial as a PC treatment.

[1]  J Waxman,et al.  Regulation of prostate cell growth and morphogenesis by Dickkopf-3 , 2006, Oncogene.

[2]  Donald C. Chang,et al.  The MicroRNA (miRNA): Overview of the RNA Genes that Modulate Gene Function , 2007, Molecular biotechnology.

[3]  J. Kench,et al.  Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression , 2004, The Prostate.

[4]  Steven Gallinger,et al.  Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. , 2007, Cancer research.

[5]  E. Rimm,et al.  Diet After Diagnosis and the Risk of Prostate Cancer Progression, Recurrence, and Death (United States) , 2006, Cancer Causes & Control.

[6]  D. Bostwick,et al.  Risk of prostate carcinoma death in patients with lymph node metastasis , 2001, Cancer.

[7]  André Kajdacsy-Balla,et al.  miR-183-96-182 Cluster Is Overexpressed in Prostate Tissue and Regulates Zinc Homeostasis in Prostate Cells* , 2011, The Journal of Biological Chemistry.

[8]  X. Agirre,et al.  Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues , 2006, Molecular Cancer.

[9]  M. Sakaguchi,et al.  Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. , 2005, Cancer research.

[10]  D. Slamon,et al.  Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas , 1997, Oncogene.

[11]  R. Dahiya,et al.  Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma , 2010, British Journal of Cancer.

[12]  E. Fearon,et al.  Cancer progression , 1999, Current Biology.

[13]  R. Stephens,et al.  Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. , 2008, Cancer research.

[14]  C. Creighton,et al.  Widespread deregulation of microRNA expression in human prostate cancer , 2008, Oncogene.

[15]  K. Miyazono,et al.  Smad4-independent regulation of p21/WAF1 by transforming growth factor-β , 2004, Oncogene.

[16]  T. Tammela,et al.  MicroRNA expression profiling in prostate cancer. , 2007, Cancer research.

[17]  Gerald C. Chu,et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.

[18]  S. Shukla,et al.  Dietary Agents in the Chemoprevention of Prostate Cancer , 2005, Nutrition and cancer.

[19]  Zhongmei Zhou,et al.  PMEPA1 promotes androgen receptor‐negative prostate cell proliferation through suppressing the Smad3/4–c‐Myc–p21$^{{\rm Cip1}}$ signaling pathway , 2011, The Journal of pathology.

[20]  Michael T. McManus,et al.  Gene silencing in mammals by small interfering RNAs , 2002, Nature Reviews Genetics.

[21]  Wenyan Lu,et al.  Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. , 2009, European journal of pharmacology.

[22]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[24]  T. H. van der Kwast,et al.  Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. , 2006, The Journal of urology.

[25]  P. Dijke,et al.  DPC4 (SMAD4) mediates transforming growth factor-β1 (TGF-β1) induced growth inhibition and transcriptional response in breast tumour cells , 1997, Oncogene.

[26]  O. Ogawa.  Risk Factors for Prostate Cancer , 2004 .

[27]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[28]  W. Cho,et al.  Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. , 2009, European journal of cancer.

[29]  Xiaofei Zheng,et al.  miR-183 inhibits TGF-β1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells , 2010, BMC Cancer.

[30]  G. Kristiansen,et al.  Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.

[31]  Subbaya Subramanian,et al.  MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. , 2010, Cancer research.

[32]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[33]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.